ASCO 2022 Archives -

Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or

ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

https://pharmaphorum.com/news/asco22-jj-pfizer-trade-bcma-bispecific-data-in-myeloma/

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast

ASCO22: Enhertu aces key HER2-low test in breast cancer

https://pharmaphorum.com/news/asco22-enhertu-aces-key-her2-low-test-in-breast-cancer/

In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of

ASCO22: Gilead makes case for Trodelvy in advanced breast cancer

https://pharmaphorum.com/news/asco22-gilead-makes-case-for-trodelvy-in-advanced-breast-cancer/

For the first time since 2019, the American Society of Clinical Oncology (ASCO) annual meeting will be an

ASCO ’22 preview: Putting patients first

https://pharmaphorum.com/views-analysis-oncology/asco-22-preview-putting-patients-first/

ASCO 2022